Why Farbe Firma is the Top Manufacturer of Granisetron HCl Injection
- Maulik Sudani
- 24 hours ago
- 7 min read
Last Updated: June 15, 2026
TL;DR: Granisetron HCl Injection — a sterile, clear, colourless aqueous solution of granisetron hydrochloride, a selective 5-HT3 (serotonin) receptor antagonist antiemetic, supplied commonly as a 1 mg/mL ampoule and a 3 mg/3 mL vial for intravenous use — is a frontline hospital agent for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting (PONV). Because the dose is given intravenously and reliable antiemetic cover depends on an accurate, reproducible dose, each ampoule or vial must deliver an exact, sterile, particulate-free amount at the labelled concentration, with the assay, the impurity and degradation profile, solution pH, fill volume, low particulate and endotoxin, a validated sterilisation route and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Granisetron HCl Injection at our Gujarat, India facility and supplies it to hospital pharmacy, oncology, anaesthesia and critical-care services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Selective 5-HT3 (serotonin) receptor antagonist antiemetic — Granisetron HCl Injection is used intravenously for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting (PONV).
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated solution compounding and ampoule/vial filling lines, control of the stability-indicating assay, the impurity profile, solution pH, fill volume, particulate and endotoxin for a low-strength small-volume parenteral, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready ampoule and vial packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Granisetron HCl Injection Demands a Premium Manufacturer
Granisetron HCl Injection holds a dependable, central place in oncology, anaesthesia, emergency medicine and critical care across every market. It is the intravenous 5-HT3 receptor antagonist that clinicians reach for to prevent and control the severe nausea and vomiting that accompany cytotoxic chemotherapy and radiotherapy, and to prevent and treat nausea and vomiting after surgery. By selectively blocking serotonin 5-HT3 receptors in the gut and the central chemoreceptor trigger zone, granisetron interrupts the emetic reflex before it overwhelms the patient — protecting nutrition, hydration, comfort and adherence to potentially life-saving cancer treatment. In each of these settings the dose delivered from each ampoule or vial must be exact, sterile, particulate-free and reliably the same from unit to unit, because dependable antiemetic cover depends on a precise, reproducible dose delivered at low strength in a small volume.
That clinical reality places real demands on the manufacturer. The product is presented as a low-strength, low-volume aqueous solution that must stay a clear, colourless solution within a defined pH window throughout shelf life and must remain compatible with the common diluents into which it is mixed for infusion. The assay of granisetron must be exact even at low concentration; the impurity and degradation profile must stay within tight limits; the pH and the deliverable volume must be controlled tightly so each unit gives the labelled dose at the labelled concentration; the solution must be free of visible and sub-visible particulates and low in endotoxin; and it must be sealed in an ampoule or vial whose container-closure integrity holds across shelf life. Choosing a Granisetron HCl Injection manufacturer that treats the stability-indicating assay, pH and fill-volume control, the validated sterilisation route, particulate and endotoxin control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Granisetron HCl Injection Manufacturer Apart
A world-class manufacturer of Granisetron HCl Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of granisetron with the tight related-substance and degradation-product control by HPLC that a low-strength parenteral antiemetic demands, a robust, validated aseptic solution-fill process — with terminal moist-heat sterilisation where the formulation and container permit it, otherwise sterile filtration and aseptic filling — that protects the assay, the pH and the clarity of the solution, and tender-ready dossier support for a hospital-formulary oncology product procured through pharmacy and ministry-of-health channels. It starts with the active — pharmacopoeial-grade granisetron hydrochloride sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend both the assay and the dose. The bulk solution is compounded in water-for-injection with the buffer and tonicity adjusters that hold granisetron stable at the controlled pH, sterile-filtered through 0.22 µm membrane, and filled into ampoules or vials under ISO Class 5 conditions, with the validated sterilisation route — terminal moist-heat where qualified, otherwise full aseptic processing — locked in the master batch record. Filled units are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm the assay of granisetron by validated HPLC, the related-substance profile, solution pH, deliverable volume, visible and sub-visible particulate matter, and endotoxin is held well within limits so the solution is safe for intravenous administration. Because granisetron is dosed at low strength, assay accuracy at low concentration and deliverable-volume control are confirmed and documented with particular rigour.
Quality Systems Behind Every Granisetron HCl Injection
Every Farbe Firma Granisetron HCl Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of granisetron against pharmacopoeial reference standards, control of related substances and degradation products by HPLC, solution pH, deliverable (fill) volume, clarity and colour of the solution, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the ampoule and vial formats. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated ampoule- and vial-filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because granisetron is given to protect patients through demanding cancer therapy and surgery and the assay, pH, clarity and particulate burden of the solution drive both efficacy and safety, we treat the stability-indicating HPLC assay, the solution pH, the deliverable volume and the related-substance profile as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, and in-use dilution stability is established to support infusion preparation.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Granisetron HCl Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad small-volume parenteral portfolio across oncology supportive-care, anaesthesia, anti-infective and critical-care categories. For Granisetron HCl Injection specifically, we supply the 1 mg/mL ampoule and the 3 mg/3 mL vial of sterile solution under WHO-GMP conditions, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay, pH, sterilisation and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Granisetron HCl Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, stability-indicating assay development, related-substance and degradation control, pH and buffer design, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose control, dilution-compatibility and in-use stability, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a low-strength parenteral antiemetic where assay accuracy, pH and particulate control directly govern both antiemetic efficacy and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Granisetron HCl Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Granisetron HCl Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, dedicated solution compounding and ampoule/vial filling lines, validated sterilisation, qualified water-for-injection systems, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Granisetron HCl Injection do you supply?
Our standard presentations are the 1 mg/mL single-dose ampoule and the 3 mg/3 mL vial of sterile granisetron hydrochloride solution, for intravenous use. Custom strengths, fill configurations, ampoule or vial formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Granisetron HCl Injection mainly used for?
Granisetron HCl Injection is used for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting (PONV). It is a selective 5-HT3 receptor antagonist; Farbe Firma verifies the assay, clarity, deliverable volume, pH and particulate matter at release so each unit delivers a precise, reproducible dose.
Can Farbe Firma support country-specific registrations for Granisetron HCl Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Granisetron HCl Injection contract manufacturing?
MOQs vary by strength, ampoule or vial size, sterilisation route, label complexity and dossier requirements. For our small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments